Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Department of Clinical Sciences, Danderyd University Hospital, Stockholm, Sweden.
J Clin Pathol. 2020 Oct;73(10):630-635. doi: 10.1136/jclinpath-2019-206300. Epub 2020 Feb 7.
Despite being one of the major pathways for the spread of malignant tumours, perineural invasion (PNI) has not conclusively been shown to have an independent prognostic value for prostate cancer. Prostatic biopsy constitutes the major pathology workload in prostate cancer and is the foundation for primary treatment decisions and for this reason we aimed to estimate the prognostic value of PNI in biopsies.
We followed 918 men who underwent radical prostatectomy (RP) from the prospective and population based STHLM3 study until biochemical recurrence with a median follow-up of 4.1 years. To strengthen the evidence, we combined the estimates from the largest studies targeting the prognostic value of PNI in the biopsy. We also estimated the OR of advanced stage as radical prostatectomy for PNI positive and negative men.
The estimated prognostic value based on our data suggested an approximately 50% increased risk of biochemical recurrence if PNI was present in the biopsy (p=0.06). Even though not statistically significant on the 5% level, this estimate is consistent with similar studies, and by combining the estimates there is in fact strong evidence in support of an independent prognostic value of PNI in the biopsy (p<0.0001). There was also an independent increased risk of advanced stage at RP for positive men (OR 1.85, p=0.005).
The evidence supporting a clinically relevant and independent prognostic value of PNI is strong enough to be considered for pathology reporting guidelines.
尽管神经周围侵犯(PNI)是恶性肿瘤扩散的主要途径之一,但它并未被明确证明对前列腺癌具有独立的预后价值。前列腺活检构成了前列腺癌的主要病理学工作量,是确定主要治疗决策的基础。因此,我们旨在评估活检中 PNI 的预后价值。
我们对前瞻性、基于人群的 STHLM3 研究中的 918 名接受根治性前列腺切除术(RP)的男性进行了随访,直到生化复发,中位随访时间为 4.1 年。为了加强证据,我们结合了针对活检中 PNI 预后价值的最大研究的估计值。我们还估计了 PNI 阳性和阴性男性接受 RP 治疗的晚期肿瘤的 OR。
根据我们的数据,估计 PNI 存在于活检中时,生化复发的风险增加了约 50%(p=0.06)。尽管在 5%的水平上没有统计学意义,但这一估计与类似的研究一致,通过合并这些估计值,实际上有强有力的证据支持活检中 PNI 具有独立的预后价值(p<0.0001)。对于阳性男性,RP 时的晚期肿瘤风险也有独立增加(OR 1.85,p=0.005)。
支持 PNI 具有临床相关和独立的预后价值的证据足够强大,可以考虑将其纳入病理学报告指南。